Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NKT3964 |
Synonyms | |
Therapy Description |
Limited information is currently available on NKT3964, a putative proteolysis targeting chimera (PROTAC) targeting CDK2 (Nov 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NKT3964 | NKT 3964|NKT-3964 | CDK2 Inhibitor 31 | Limited information is currently available on NKT3964, a putative proteolysis targeting chimera (PROTAC) targeting CDK2 (Nov 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06586957 | Phase I | NKT3964 | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |